Marginal ulceration, or ulceration at the gastrojejunal anastomosis, is a common complication of Roux-en-Y gastric bypass (RYGB). Acidity likely contributes to the pathophysiology, and proton pump inhibitors (PPIs) frequently are prescribed for treatment. However, patients with gastric bypass only have a small gastric pouch and rapid small-bowel transit, which limits the opportunity for capsule breakdown and PPI absorption. 
T he increasing worldwide prevalence of severe obesity and associated comorbidities has resulted in a substantial increase in the number of bariatric procedures performed annually. 1, 2 In fact, bariatric surgery has become one of the fastest-growing surgical procedures performed worldwide, and has gained acceptance as the leading sustained weight-loss option for morbid obesity. 3 Although the performance of bariatric surgery has continued to improve over the past decade, complications from the procedures are not uncommon.
Roux-en-Y gastric bypass (RYGB) is one of the most commonly performed procedures globally. One of the long-term complications after RYGB is the development of an ulcer around the gastrojejunal anastomosis, known as a marginal ulceration. The reported occurrence of marginal ulceration is as high as 16%. [6] [7] [8] [9] [10] [11] There is substantial evidence that acidity plays a major role in the disease pathophysiology given that the jejunum receives the acidic chyme from the stomach pouch in the absence of the duodenum's intrinsic acidbuffering properties. Studies have shown that patients with increased acid in the stomach pouch, and increased exposure to an acidic pH, were at increased risk for marginal ulceration. 12 Furthermore, a recent systemic review and meta-analysis found significant incremental benefit of use of prophylactic proton-pump inhibitors (PPIs) in reducing marginal ulceration after gastric bypass surgery. 13 As such, the mainstay of treatment is high-dose PPIs. However, there is no consensus on the formulation or dose of therapy.
14 Use of soluble PPIs, or opening capsules, also has been used in an attempt to enhance absorption in bypass patients.
PPI capsules are designed to break down in the stomach. Patients with gastric bypass only have a small gastric pouch, and rapid small-bowel transit, limiting the opportunity for capsular breakdown and medication absorption. Some capsules even may make their way to the colon before breakdown occurs. These factors may lead to variable treatment effects, which may be overcome by use of a soluble form of PPI.
The primary aim of the current study was to compare time to healing of marginal ulceration in RYGB patients receiving PPIs in OC vs IC form. Secondary aims included comparison of the number of endoscopic procedures and health care utilization in patients receiving OC vs IC PPI administration.
Methods

Data Source
This was a retrospective review of a prospectively collected database in patients from 2000 to 2015. All patients who underwent RYGB were enrolled prospectively in the Research Patient Data Registry, and all patients found to have marginal ulceration on endoscopy were reviewed for inclusion in this analysis.
Study Sample
Endoscopic reports were reviewed retrospectively from all post-RYGB patients diagnosed with marginal ulceration who were referred to our institution between January 2000 and December 2015. Patients were included in analyses if they were placed on maximum medical management including therapy with high-dose PPI, and if repeat endoscopy was performed as per hospital protocol until ulcer healing was confirmed. High-dose PPI was defined as including any of the following regimens: omeprazole (Prilosec, Cincinnati, OH) 20 mg or 40 mg twice a day, pantoprazole (Protonix, New York, NY) 20 mg or 40 mg twice a day, esomeprazole (Nexium, Wilmington, DE) 20 or 40 mg twice a day, or soluble lansoprazole (Prevacid, Deerfield, IL) 30 mg twice a day. The particular regimen of PPI administration (open vs intact capsules) was dependent entirely on the provider to which the patient was assigned, and each provider was consistent with the form of PPI prescribed. Providers were assigned based on availability at the time the patient requested an appointment.
Patients were scheduled for repeat endoscopies every 3 months until ulcer healing was confirmed and patients who did not undergo surveillance endoscopy within the first year of ulcer diagnosis were excluded from the study. Patients also were excluded if information regarding the method of PPI administration was unavailable, or if noncompliance to PPIs was elicited and documented in the medical record.
Study Variables
Patient charts were reviewed under an approved institutional review board protocol. Patient demographics collected from the Research Patient Data Registry included age (assessed as a continuous variable), sex, pre-RYGB body mass index, and smoking status. Information regarding approach (open vs laparoscopic), date of bariatric surgery, subsequent endoscopic procedure(s), emergency room visits, and radiographic studies were obtained for each patient. In addition, medication dosages and modes of administration (PPIs, sucralfate, nonsteroidal anti-inflammatory drugs [NSAIDs] ), in addition to other known or suspected risk factors for the development of marginal ulceration (including Helicobacter pylori status and diabetes) were determined.
The total charge (procedural and maintenance), reflecting relative health care utilization, was determined by comparison of categorized charges incurred from the time of ulcer diagnosis to the time of resolution. The charge count was stopped on the day of ulcer resolution or at the time of alternative therapy, such as surgery. All charges related to ulcer management including procedural, medication, and Emergency Department visit were obtained. Professional fees used 2014 Medicare rates for metropolitan Boston.
Outcomes
The primary outcome of the current study was to compare the time to healing of marginal ulceration in RYGB patients receiving high-dose proton pump inhibitors in OC vs IC form. Secondary aims included comparison of the number of endoscopic procedures and health care utilization in patients receiving OC vs IC PPI administration.
Subgroup Analyses
Subgroup analyses were performed to determine whether PPI dose (ie, 1 dose 2 times per day, or 2 doses 2 times per day) predicted time to healing of marginal ulceration in the OC group.
Subgroup analyses also were performed in RYGB patients receiving only high-dose PPI administration in OC vs IC forms, and not receiving simultaneous sucralfate therapy.
Statistical Analysis
The Fisher exact test for binary variables and the Student t test or Wilcoxon signed-rank test for continuous variables based on normality of the data were applied to assess baseline differences across IC and OC groups. The Kaplan-Meier method was used to construct time-to-event curves, with log-rank testing to assess differences in time-to-event relationships. Survival analysis with the Cox proportional hazard model was performed to identify the association between mode of PPI administration and time to healing of marginal ulceration. Other variables included in the Cox proportional hazard model were risk factors for ulcer healing (age, presence of fistula, foreign body material such as suture/staple, gastric pouch length, smoking status, NSAID use, and H pylori infection). The year the gastric bypass surgery was performed and the year the diagnosis of marginal ulceration was made also were included in a separate analysis to determine whether a change in surgical technique over time affected the results. All statistical analyses were performed using the SAS 9.4 statistical package (SAS Institute, Inc, Cary, NC). The study was approved by the Institutional Review Board before inception. Figure 1 shows the flow diagram for study inclusion. A total of 402 patients were screened for inclusion in the study. A total of 162 patients fit inclusion criteria. The mean age of the cohort was 51.8 AE 0.6 years, and 82.3% of patients included were female. Pre-RYGB body mass index was 47.0 AE 0.6 kg/m 2 . The mean (AESEM) time to diagnosis of marginal ulceration was 3.9 AE 0.3 years after RYGB. The total number of marginal ulcerations diagnosed per year is shown in Supplementary Figure 1. A total of 115 patients opened PPI capsules and 49 did not. The baseline differences between these groups are shown in Table 1 . The groups were comparable in regard to demographic variables and distribution of known risk factors leading to the development of marginal ulceration.
Results
Patient Characteristics
Time to Ulcer Healing
Baseline risk factors for the development of marginal ulceration were assessed by Wilcoxon and time-to-event analyses to address for possible confounding; only the addition of sucralfate was statistically significant ( Table 2 ). The median time to ulcer healing was 91.0 vs 342.0 days for the OC vs IC groups, respectively (P < .001).
By using a Cox proportional hazard model, patients in the OC group had a significantly decreased time to ulcer healing (hazard ratio, 6.04; 95% confidence interval, 3.74-9.06; P < .001) when compared with patients in the IC group. The Kaplan-Meier curve confirmed this relationship across these 2 groups (log-rank P ¼ .001) (Figure 2 ). Opening capsules was the only independent predictor of time to ulcer healing when controlling for PPI dose, sucralfate, and known risk factors for the development of marginal ulceration including diabetes, presence of fistula, foreign material (suture/staple), smoking, NSAID use, and H pylori infection ( Table 3 ). The addition of year of RYGB and year of marginal ulcer diagnosis did not change the final model, and neither was significant on the univariate analysis. Although the addition of sucralfate was statistically different on univariate analysis, it was not an independent predictor of time to ulcer healing in the final multivariable model when controlling for other covariates.
Subgroup Analyses
Subgroup analyses showed no differences in the median time to ulcer healing and PPI dose (ie, whether it was administered as 1 dose 2 times per day, or as 2 doses 2 times per day) when assessed separately as individual outcomes. No significant complications were linked directly to the use of high-dose PPIs during the study period.
In addition, when excluding patients who simultaneously were receiving sucralfate therapy, the median time to ulcer healing was 89.5 vs 370.0 days for OC vs IC groups, respectively (P < .001). The Cox proportional hazard model for this subgroup analysis similarly showed that patients in the OC group had a significantly decreased time to ulcer healing (hazard ratio, 7.72; 95% confidence interval, 3.48-17.07; P < .001) when compared with patients in the IC group. Furthermore, opening capsules continued to be the only independent predictor of time to ulcer healing when controlling for all other risk factors in the original multivariable model.
Health Care Use
The mean number of endoscopic procedures required was 1.24 AE 0.05 and 1.82 AE 0.25 in the OC vs IC groups, respectively (P ¼ .02). Total health care utilization was significantly lower for patients who opened PPI capsules compared with patients who ingested the intact form ($7206 vs $11,009; P ¼ .05). Categorized charges are compared in Table 4 . Specifically, the mean endoscopicrelated, medication-related, and total costs all were significantly lower in the OC vs IC groups.
Discussion
Marginal ulceration at the site of the gastrojejunal anastomosis is a recognized complication in patients after RYGB. [6] [7] [8] [9] [10] 14, 15 Although the treatment of marginal ulceration with PPI administration is accepted internationally and advised in a variety of different guidelines, 16, 17 there is little consensus on dose or formulation.
14 No studies to date have compared differences in healing time between patients taking open or soluble forms of this medication and those taking intact capsules.
The present study compared these 2 methods of PPI administration. We showed shorter ulcer healing times in patients taking a soluble form of this medication compared with patients who were taking intact capsules. Furthermore, when controlling for the use of sucralfate and risk factors that are known to lead to the development of marginal ulceration including diabetes, presence of fistula, foreign material (suture/staple), smoking, NSAID use, and H pylori infection, taking PPI capsules in a soluble form was the only independent predictor of days to ulcer healing.
The occurrence of marginal ulceration in the literature varies between 0.6% and 16%. [6] [7] [8] [9] [10] [11] [12] The clinical presentation can range from no symptoms to having severe pain and obstructive symptoms or gastrointestinal bleeding, and rarely can present as perforation.
The mechanisms underlying the development of marginal ulceration have not been elucidated fully. 8, [18] [19] [20] The etiology likely is multifactorial, with location and size of the gastric pouch, gastrogastric fistula, and the presence of foreign material or ischemia at the site of anastomosis all potentially playing a role in the pathogenesis. 6, 10, 21, 22 Furthermore, several patientrelated factors such as smoking, diabetes, NSAID use, and H pylori infection have been proposed as risk factors associated with the development of this complication. 8, 20 Given the substantial evidence that acidity plays a major role in the disease pathophysiology, the treatment of marginal ulceration with PPI is essential for ulcer healing. 16, 17 In addition, elimination of potential risk factors and endoscopic surveillance to monitor healing both play a crucial role in the management of this condition. Unlike the more common peptic ulcers, which typically heal within 8 weeks, these lesions tend to require more prolonged therapy, with studies showing a mean healing time of 7 months, with published success rates of conservative therapy ranging between 68% and 88%. 9, 19, 23 For refractory ulceration, endoscopic techniques with ulcer oversewing or surgical reoperation may be necessary. 10, 24, 25 Evidence-based guidelines or data from randomized controlled trials on the management of marginal ulcerations are lacking. A recent consensus among expert bariatric surgeons on preventative and therapeutic strategies against marginal ulceration after RYGB surgery found that the majority of bariatric surgeons use PPI as the first-line and single treatment, however, there was no consensus on dose or duration of therapy. 14 The present study showed a significant benefit of soluble PPIs over intact capsules, which may enhance the delivery and absorption, in the management of this complication. Interestingly, although the addition of sucralfate was statistically different on univariate analysis, it was not an independent predictor of time to ulcer healing in the final multivariable model when controlling for other covariates. The difference in use of sucralfate found between the groups could have to do with different practices among practitioners; controlling for the use of this medication in the multivariable analysis effectively controls for potential confounding. However, to be certain, we also ran subgroup analyses on patients receiving open vs closed PPI capsules, and excluded all patients who were receiving simultaneous sucralfate therapy. These analyses yielded the same results, further confirming our findings. In addition, these results are consistent with many previous studies showing a lack of definitive benefit to this medication.
The improvement in time to ulcer healing observed in patients who ingested the open capsule or soluble form of PPIs has tremendous implications from a health care utilization standpoint. As we have shown, patients with marginal ulceration undergo fewer endoscopic procedures and have significantly lower overall health care utilization when ingesting a soluble PPI, as compared with those who ingest the intact form.
There were several strengths of this study. First, this was a large study that evaluated medical therapy for marginal ulceration healing in post-RYGB patients. Second, as a large referral center for postbariatric surgery patients, we have a standard protocol for endoscopic and postendoscopic management, with the exception of PPI formulation, thereby minimizing variation in practice among providers. Third, these data were collected prospectively, minimizing potential recall biases inherent to retrospective databases. Fourth, our treatment end point was based on objective endoscopic assessment of ulcer healing. Finally, these patients were followed up longitudinally until ulcer healing was confirmed.
There also were limitations of this study. First, upper endoscopy was performed predominantly in symptomatic patients, thereby missing all asymptomatic patients, 7, 26 However, in light of the fact that routine postsurgical gastroscopy is not recommended in asymptomatic patients given the low yield and invasiveness of such a procedure, it would be difficult to capture this group. Another limitation was the definition used for study inclusion, which required endoscopic surveillance after diagnosis. These were performed every 3 months in the majority of patients, with some patients waiting longer intervals. Nevertheless, the exact time of healing is not possible to discern. We would not expect there to be a difference between groups, and we confirmed that the average time to first surveillance endoscopy was similar between groups. Furthermore, a substantial number of patients were excluded from the analysis as a result of loss to followup evaluation or noncompliance with endoscopic surveillance. In addition, because of the rigorous treatment algorithm applied uniformly to both groups at our institution emphasizing smoking cessation, minimization of NSAID use, and early H pylori treatment, these factors were not found to be independent predictors of ulcer healing between groups. Finally, given the retrospective nature of this study, it is possible that selection bias may have affected the results. However, this was minimized by several factors. First, the particular regimen of PPI administration (open vs intact capsules) was dependent entirely on the provider to which each patient was assigned, and each provider was consistent with the form of PPI prescribed. Second, in the present study, degree of ulceration did not influence treatment because providers were consistent in prescribing an open or closed form of PPI to their patients, and did not vary based on the severity of ulceration. Third, the administration of a particular regimen was independent of a particular time or date cut-off point because those who were prescribing open (or closed) PPIs were doing so at the conception of this database. We incorporated both the year of the patient's gastric bypass and the year of the patient's diagnosis of marginal ulceration within our univariate analysis and multivariable model. Neither of these variables was significant in the analysis, again suggesting that practice changes over time (including improvement in surgical technique or management of ulcerations) did not play a role in the present study. Finally, insurance covers a capsule or soluble form of PPI in all cases, limiting a factor often seen in retrospective studies that is biased based on insurance coverage.
In conclusion, there is no consensus regarding the management of marginal ulceration. The present study compared time to healing and health care expenditure of marginal ulceration between PPI formulations. Although no difference was found between PPI classes, ulcer healing with soluble forms was faster and resulted in lower health care utilization. Given these results and the high prevalence of marginal ulceration in this patient population, further study in a randomized controlled setting is warranted, and use of OC PPIs should be considered as a low-risk, low-cost alternative.
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